uPA-uPAR拼接结合变化与肝硬化患者恶变趋势的相关性研究  

Correlation between uPA-uPAR Splicing Combination Changes and Aggravations in Liver Cirrhosis Patients

作　　者：周英群[1] 吕小平[1] 李山[1] 覃锦耀[1] 詹灵凌[1] 

机构地区：[1]广西医科大学第一附属医院检验科,南宁530021

出　　处：《现代检验医学杂志》2013年第5期75-76,80,共3页Journal of Modern Laboratory Medicine

基　　金：广西科学基金资助项目（桂科基：0731067）.

摘　　要：目的 探讨引起尿激酶型纤溶酶原激活物及其可溶型受体比值（uPA/suPAR）及uPA-uPAR拼接结合的变化与肝硬化恶变趋势的相关性.方法 选择2008年8月～2010年4月肝硬化初诊患者133例,经3年随访后分为病情稳定组和恶变组,应用酶联免疫法（ELISA）检测其血浆中uPA和suPAR水平,采用免疫组化法检测初诊患者、恶变组的uPA及其受体（uPAR）在组织中的表达.结果 肝硬化恶变组uPA/suPAR值较稳定组患者有显著升高,差异有统计学意义（t=5.626,P=0.00〈0.05）;肝硬化初诊患者与稳定组比较差异无统计学显著性意义（t=1.19,P=0.24〉0.05）.uPA和uPAR在恶变组患者组织中的阳性表达率比初诊患者明显增高,比较差异均有统计学意义（χ2=5.443～6.091,P值均〈0.05）.结论 uPA/suPAR比值的变化可能存在uPA-uPAR拼接变异体结合的改变,其与肝硬化患者恶变趋势密切相关.Objective To explore the correlation between the changes of uPA/suPAR ratio,uPA-uPAR splicing combination and the aggravations in liver cirrhosis patients. Methods Selected 133 case of first diagnosis liver cirrhosis patients, they were divided into stable group and malignant group after three years follow-up,and used the ELISA method for detecting the plasma uPA,suPAR levels and the immunohistochemieal method for detecting the expression of uPA, uPAR in their tissues. Results The uPA/suPAR ratio of the cirrhosis malignant group was significantly higher than that in stable group （t= 5. 626, P=0. 00〈0. 05）. Compared with two groups between the first diagnosis liver cirrhosis patients and the stable group, there was no significant statistical significance difference （t= 1.19, P= 0. 24〉0. 05）. The uPA, uPAR positive expression rate in the malignant group was significantly higher than that in the initial diagnosis patients with liver cirrhosis, compared with the differences between the two groups, there was statistically significant （X^2 = 5. 443 - 6. 091, P〈0.05）. Conclusion The change of uPA/suPARratio maybe caused by the change of uPA-uPAR splice varients which is close related to the ag-gravations in liver cirrhosis.

关 键 词：肝硬化 尿激酶型纤溶酶原激活物 尿激酶型纤溶酶原激活物可溶型受体 uPA-uPAR拼接变异 

分 类 号：R575.2[医药卫生—消化系统] R392.11[医药卫生—内科学]